Replies to post #20 on DermTech Inc (DMTK)

[TallTrader]

Lake Street Capital Markets Analyst Thomas Flaten initiated coverage of DermTech, Inc. with a BUY rating and price target of $15 (DMTK $7.60).

DermTech is a molecular diagnostics company developing and marketing novel gene expression-based tests for various dermatologic applications, including the Pigmented Lesion Assay for the diagnosis of melanoma. Combining gene expression assays with the Company’s adhesive patch technology allows for non-invasive testing. In addition to advancing a proprietary pipeline of diagnostic tests, the Company also partners with pharmaceutical companies for the use of its core technology in clinical studies.

[greens12]

The float is getting locked up, not much left for retail......I was watching the warrants sky rocket today congrats to you. Medicare news will be explosive as more people find out about the revenues coming .

DMTK